Jeevan Scientific Technology reported a significant turnaround in profitability for the first quarter of FY27, with standalone net profit rising to ₹188.60 lakh from a net loss of ₹215.99 lakh in Q1FY26. Consolidated net profit also improved, reaching ₹86.97 lakh, up 68.7% year-on-year from a loss of ₹126.22 lakh.

The Hyderabad-based clinical research services company saw its standalone revenue from operations decline 8.4% quarter-on-quarter to ₹1,693.47 lakh, though it remained 106.1% higher than the ₹821.57 lakh recorded in Q1FY25. Consolidated revenue fell 14.1% QoQ to ₹1,827.75 lakh but surged 81.7% YoY compared to ₹1,005.79 lakh in the prior year period.

Financial Performance

The company’s operational efficiency improved alongside the profit turnaround. Standalone other expenses decreased significantly to ₹676.85 lakh from ₹845.64 lakh in the preceding quarter, contributing to the bottom-line recovery despite a slight dip in top-line sales. Employee benefit expenses remained stable at ₹494.67 lakh, including ₹14.05 lakh towards ESOP expenses.

On a consolidated basis, the group benefited from lower inventory changes and controlled employee costs, which stood at ₹44.09 lakh. However, finance costs increased to ₹170.27 lakh from ₹177.08 lakh in the prior year, reflecting ongoing debt servicing obligations. The share of profit from associates remained negligible at a loss of ₹0.69 lakh.

What the Numbers Show

A key divergence exists between the standalone and consolidated results. While the standalone entity posted a robust net profit margin of approximately 11.1%, the consolidated group’s margin was thinner at roughly 4.7%. This spread is primarily driven by the performance of subsidiaries and associates, notably Nayas Laboratories Private Limited, which reported a net loss of ₹100.94 lakh for the quarter according to the auditor’s review report. This indicates that while the core clinical research operations are profitable, subsidiary investments continue to weigh on group-level profitability.

Corporate Actions

During its meeting on August 13, 2026, the Board of Directors approved several key administrative and governance matters:

• Re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for three years effective November 2, 2026.
• Continuation and re-appointment of Mr. Nageswar Rao Yarllagadda as Whole Time Director beyond age 70, effective June 23, 2027.
• Appointment of Mr. Kolli Srinivas Rao as an additional Independent Director effective immediately.
• Scheduling of the Annual General Meeting for FY26 on September 25, 2026, via video conferencing.

Pavuluri & Co., the statutory auditors, issued a limited review report on the interim financial results, stating that nothing came to their attention to cause them to believe the statements contained material misstatements.

Jeevan Scientific Technology Limited has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) to expand the bed capacity at its Bioavailability/Bioequivalence (BA/BE) Study Centre in Hyderabad. The expansion increases the facility’s capacity from 132 general beds and 06 ICU beds to 156 general beds and 08 ICU beds, enhancing the company’s ability to conduct higher volumes of clinical studies.

The approval follows a successful regulatory inspection conducted by the CDSCO on June 24, 2026. Jeevan Scientific Technology submitted an application for the enhancement, which was processed under the existing regulatory framework. The company disclosed the development on August 01, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Facility Expansion Details

The study centre is located at Plot No. B-17, TIE Phase II, Balanagar, Hyderabad-500037, Telangana. The approved changes reflect a strategic upgrade to the company’s clinical research infrastructure.

The increase allows for a net addition of 24 beds across both categories. This infrastructure upgrade is designed to strengthen operational capabilities and support future business growth through increased study throughput.

Operational Impact

Management indicated that the enhanced capacity will enable the company to undertake a higher volume of Bioavailability/Bioequivalence studies. The expansion addresses potential bottlenecks in scheduling and patient accommodation, allowing for more efficient trial execution.

Jeevan Scientific Technology emphasized its commitment to maintaining high standards of quality, regulatory compliance, and patient safety. The company stated that the upgraded facility will continue to adhere to strict regulatory protocols while expanding its service offerings to clients in the pharmaceutical sector.

What the Numbers Show

The expansion represents a 17.4% increase in total bed capacity (from 138 to 164 beds). While the general bed capacity grows by 18.2%, the ICU bed capacity sees a larger proportional jump of 33.3% (from 06 to 08 beds). This disproportionate increase in ICU beds suggests a strategic focus on handling more complex or high-risk clinical trials that require intensive monitoring, potentially allowing the company to bid for more specialized and higher-value contracts in the CRO space.